Northway Biotech
16.5.2023 14:32:41 CEST | ACCESS Newswire | Press release
KIEL, GERMANY / ACCESSWIRE / May 16, 2023 / tiakis Biotech AG (tiakis), in collaboration with its CDMO partner Northway Biotech, is pleased to announce the successful completion of a technology transfer and ramp-up of manufacturing capabilities for Tiprelestat, a pioneering anti-inflammatory and tissue-protective drug being developed for the prevention of postoperative inflammatory complications following major surgery, treatment of COVID-19 and pulmonary arterial hypertension. For the first time worldwide, a clinical trial is being supported by Tiprelestat study material produced at an industrial fermentation scale, representing a ten-fold increase in manufacturing potential to 3,000 L.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.tiakis Biotech AG and Northway Biotech: Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat
"The marked increase in manufacturing capabilities lays the foundation for the next stage of tiakis' development programs, with the recent start of our COMCOVID phase Ib/II clinical trial being a prime example," said Martin Voss, tiakis Biotech AG co-CEO.
The enhanced production capabilities is a result of the successful completion of a technology transfer and subsequent ramp-up program, achieved in a short time through close collaboration with end-to-end biologics CDMO Northway Biotech, based in Vilnius, Lithuania.
Reflecting on this milestone, Vladas Algirdas Bumelis, CEO of Northway Biotech, stated: "The confidence our partners have placed in our two-decade-long expertise has enabled us to collaboratively scale up the process and meet tiakis' deadlines. Our state-of-the-art 3,000 L stainless-steel fermenter train was utilized to carry out the implementation successfully. We extend our sincere well-wishes to our partners as they move forward with their innovative drug through clinical trials, and we look forward to future collaborations."
André Markmann, VP Business Development of Northway Biotech, added: "This partnership exemplifies our commitment to assist our partners in achieving their objectives by leveraging our technical expertise and operational capabilities. We are immensely proud to be part of this groundbreaking project, which addresses a significant unmet medical need."
By attaining this pharmaceutical and technological milestone, tiakis and Northway Biotech have demonstrated their capabilities to pave the way towards groundbreaking achievements as pioneers in their respective fields. The success of this fast-paced project is characterized by strong collaborative interaction, mutual trust, and flexibility between the two companies.
About Tiprelestat
tiakis biopharmaceutical drug candidate Tiprelestat promises an excellent therapeutic benefit-risk profile for use as an anti-inflammatory and tissue-protective drug. Tiprelestat is identical to the human protein elafin with high specificity for tissue-destroying and inflammation-promoting proteases. The development program of Tiprelestat is focused on the late-stage development of Tiprelestat in major surgery and early-stage development in pulmonary arterial hypertension (PAH) and COVID-19.
About tiakis Biotech AG
tiakis focuses on the discovery and development of therapeutic solutions based on its innovative biopharmaceutical Tiprelestat for life-threatening surgeries and life-threatening diseases such as PAH and COVID-19. tiakis seeks partners and investors for the development, commercial-scale manufacturing, marketing and distribution of the product. The company tiakis Biotech AG is located in Kiel, Germany (www.tiakis.bio).
About Northway Biotech
Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and located in Vilnius, Lithuania, London, United Kingdom, and in Waltham, MA, US. Further information can be found on Northway's website www.northwaybiotech.com.
Contact Information
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
SOURCE: Northway Biotech
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/755218/tiakis-Biotech-AG-and-Northway-Biotech-Successful-Tech-Transfer-and-Expansion-of-Manufacturing-Capabilities-for-Tiprelestat
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Formerra Appoints Matt Borowiec as Chief Commercial Officer1.5.2026 15:00:00 CEST | Press release
CLEVELAND, OH / ACCESS Newswire / May 1, 2026 / Formerra, a leading distributor of performance materials, today announced the appointment of Matt Borowiec as Chief Commercial Officer (CCO). Borowiec will lead the company's commercial organization to support continued growth and global expansion while strengthening sales execution and customer success. Borowiec is a seasoned executive with over 25 years' experience in operations, commercial and P&L roles across resin manufacturing, specialty compounding, and distribution, including leadership roles at GE Plastics, PolyOne (now Avient), Transcendia, Celanese, and Kinsley Group. With this background, he is well positioned to lead Formerra's commercial strategy at this important time in the company's evolution. "Matt brings a unique combination of producer‑side and distribution experience that positions him well to strengthen alignment between our suppliers, customers, and commercial teams," said Tom Kelly, Chief Executive Officer at Forme
Global Experts call for Paradigm Shift in Medicine, Health and Education to Save Lives and Fight Escalating Health Crisis1.5.2026 14:48:00 CEST | Press release
INNSBRUCK, AUSTRIA / ACCESS Newswire / May 1, 2026 / A global consortium of 64 experts (72 entities, 5 continents) unveiled two coordinated consensus plus policy brief reports, outlining a science‑driven roadmap to confront escalating health crises and to tackle the growing burden of noncommunicable diseases (NCDs-including cardiovascular diseases, cancer, diabetes, etc.: 75% of global deaths; 82% in low-/middle income countries; 90% of all death in European region). The centerpiece is HEAL-Healthy Eating & Active Living, ideally whole‑food plant‑predominant/vegetarian-vegan diets & daily exercise outdoors/active mobility-as the minimum, first‑line standard in health and care. The authors urge immediate action on Prevention-over-Treatment and reforming education and human‑relevant science (drug failure rate from animal studies is 90-95%, and as high as 99.6% for Alzheimer disease), with a rapid shift from disease‑centered reaction to person‑centered, lifestyle‑first cure and care. Figu
Datavault AI and CyberCatch Announce Signing of Binding Letter of Intent for Datavault AI to Acquire CyberCatch to Accelerate AI-Driven, Quantum-Resistant Cyber Risk Mitigation Solutions1.5.2026 14:00:00 CEST | Press release
Strategic acquisition is anticipated to position Datavault AI to bring CyberCatch's AI-enabled cyber risk mitigation solution into Datavault AI's SanQtum-secured edge Graphics Processing Unit ecosystem, addressing a global information security market projected to reach $240 billion in 2026 (Gartner) CyberCatch's post-quantum cryptography conversion plan is also expected to position the combined company ahead of the AI-enabled "Q-Day" quantum-attack horizon, now compressed to as early as 2029 (Google) AI-enabled adversary attacks in 2025 rose 89% year-over-year while average eCrime breakout time fell to 29 minutes, a 65% increase in adversary speed compared to 2024, per CrowdStrike's 2026 Global Threat Report, and Google Quantum AI research has now compressed the timeline for cryptographically relevant quantum computing to as early as 2029. PHILADELPHIA, PA AND SAN DIEGO, CA / ACCESS Newswire / May 1, 2026 / Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a provider o
Securitas Healthcare Acquires ZulaFly(TM) to Advance Cloud-Based RTLS and Accelerate Innovation Across Healthcare1.5.2026 14:00:00 CEST | Press release
LINCOLN, NE / ACCESS Newswire / May 1, 2026 / Securitas Healthcare, a leading provider of real‑time visibility and protection solutions for the healthcare industry, is proud to announce the acquisition of ZulaFly, a healthcare‑focused Real‑Time Location System (RTLS) and staff safety technology company known for its modern, cloud‑based platform. ZulaFly's cloud-based RTLS platform delivers real-time visibility and actionable insights through a flexible, data-driven architecture. Built as a single SOC 2 Type II-compliant instance, ZulaFly offers an intuitive user experience, easy configuration, standardized data models, centralized analytics, and simplified system management. This approach enables healthcare organizations to deploy faster, gain insights sooner, and reduce long-term total cost of ownership (TCO). "This acquisition aligns with our focus and commitment to delivering best‑in‑class RTLS solutions across both cloud-based and on-premise options, keeping our healthcare clients
Datavault AI Schedules Conference Call to Discuss First Quarter 2026 Financial Results on Friday, May 15, 202630.4.2026 21:00:00 CEST | Press release
PHILADELPHIA, PA / ACCESS Newswire / April 30, 2026 / Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a provider of data monetization, credentialing, digital engagement, and real‑world asset ("RWA") tokenization technologies, today announced that it will report financial results for its first quarter of 2026 prior to market open on Friday, May 15, 2026. Following the release, Datavault AI will host a conference call and live webcast on the same day, at 8:30 a.m. ET. Conference Call and Webcast Information Date: Friday, May 15, 2026, at 8:30 a.m. ET Participant Dial-in (US): 1-877-709-8150 Participant Dial-in (International): 1-201-689-8354 -- or Click HERE for participant International Toll-Free access numbers Webcast Access: Click Here Datavault AI CEO, Nathaniel Bradley, and CFO Brett Moyer, will be presenting. A replay of the webcast will be made available later in the day in the Investors/Presentations section of the Datavault AI website: Click Here About Datavau
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom